NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

$1.88
-0.05 (-2.59%)
(As of 04/24/2024 ET)
Today's Range
$1.86
$1.95
50-Day Range
$1.73
$2.55
52-Week Range
$1.51
$3.38
Volume
533,372 shs
Average Volume
781,148 shs
Market Capitalization
$284.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.83

Erasca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
317.8% Upside
$7.83 Price Target
Short Interest
Bearish
9.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.92) to ($0.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

634th out of 909 stocks

Pharmaceutical Preparations Industry

286th out of 423 stocks

ERAS stock logo

About Erasca Stock (NASDAQ:ERAS)

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

ERAS Stock Price History

ERAS Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Erasca (NASDAQ: ERAS)
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
ERAS Mar 2024 2.000 put
ERAS Mar 2024 2.500 call
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2024
Today
4/24/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.83
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+299.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-125,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.10 per share

Miscellaneous

Free Float
106,349,000
Market Cap
$296.92 million
Optionable
Optionable
Beta
1.10
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 52)
    Co-Founder, Chairman & CEO
    Comp: $940.32k
  • Dr. David M. Chacko M.D. (Age 40)
    CFO & Chief Business Officer
    Comp: $616.76k
  • Dr. Michael D. Varney Ph.D. (Age 66)
    Chairman of Research & Development, Scientific Advisory Board Member and Director
    Comp: $83.26k
  • Dr. Nik Chetwyn Ph.D.
    Chief Operating Officer
  • Mr. Ebun S. Garner J.D. (Age 52)
    Esq., General Counsel & Corporate Secretary
    Comp: $510.98k
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 57)
    M.S., Senior Vice President of Finance
  • Ms. Chandra D. Lovejoy M.S. (Age 53)
    Chief Regulatory Affairs Officer
  • Dr. Robert Shoemaker Ph.D. (Age 43)
    Senior Vice President of Research
  • Dr. Shannon R. Morris M.D. (Age 54)
    Ph.D., Chief Medical Officer

ERAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Erasca stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ERAS shares.
View ERAS analyst ratings
or view top-rated stocks.

What is Erasca's stock price target for 2024?

5 equities research analysts have issued 12-month price targets for Erasca's shares. Their ERAS share price targets range from $6.00 to $11.00. On average, they predict the company's share price to reach $7.83 in the next year. This suggests a possible upside of 317.8% from the stock's current price.
View analysts price targets for ERAS
or view top-rated stocks among Wall Street analysts.

How have ERAS shares performed in 2024?

Erasca's stock was trading at $2.13 at the beginning of the year. Since then, ERAS shares have decreased by 12.0% and is now trading at $1.8750.
View the best growth stocks for 2024 here
.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ERAS earnings forecast
.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04.

What ETFs hold Erasca's stock?

ETFs with the largest weight of Erasca (NASDAQ:ERAS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

When did Erasca IPO?

Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

Who are Erasca's major shareholders?

Erasca's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.01%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends
.

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ERAS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners